IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Momentum Continues with Presentations at ASCO and ESMO Imunon, Inc. (NASDAQ:IMNN) has a number of important events planned for June 2025 that we ...

Drs Olga Brieieva and Martin Higgs discuss in vitro genomic models for predicting clinical resistance to PARP inhibitors for ...

Notably, the ARCHES trial had the longest median follow-up among ARPI trials at 61.4 months. During this period, median overall survival was not reached in either treatment arm. At 5 years, 66% (two ...

A substantial proportion of familial breast cancers have mutations within the BRCA2 gene. The product of this gene has been implicated in DNA repair and in the regulation of transcription. We have ...

Worse OS was noted in PALB2 PV carriers with ER+ breast cancer (HR:1.5, 95%CI: 0.9 – 2.2, p=0.09), although it did not reach statistical significance. Similar HR estimates for OS as with ER+ breast ...

Background: Obesity and hyperinsulinemia are associated with increased fallopian tube (FT) epithelial DNA damage in women carrying germline BRCA1/2 mutations. Whether these states impact survival in ...

Read our 2026 Honda HR-V review for information on ratings, pricing, specs, and features, and see how this SUV performed in our testing.

Free MLB home run picks, odds for May 26: Oneil Cruz among best bets for Monday HR player props SportsLine's model is up 24.75 units on HR picks in the last 48 days.

BRCA1 or BRCA2 genes are more common in young women, and these mutations increase cancer risk by as much as 84%. Six percent of all breast cancer patients carry BRCA gene mutations, but in ...

MUMBAI: HR and KC Colleges released their first merit lists for FY admissions 2025-26, showing slight changes in cut-offs compared to last year. Monday, Jun 23, 2025. New Delhi o C.

Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral ...